ERBB2 and breast cancer: Although expression of the target receptor VEGFR2 was not associated with any subtype in TCGA data (Fig. 5b), it was significantly overexpressed in HER2+ breast cancer in METABRIC (Fig. 5c, p-value of 4 × 10−3).